Protected and unprotected triols for prostaglandin synthesis

Details Protected and unprotected triols for prostaglandin synthesis Protected and unprotected triols for prostaglandin synthesis

2006-11-28

2006-11-28

Witherspoon, Sikarl A. (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Oxygen containing

C549S381000, C549S462000

Reexamination Certificate

active

07141706

ABSTRACT:
A process for the preparation of prostaglandin compounds having the formula (I):wherein A is selected from the group consisting of C1–C6alkyl groups; C7–C16aralkyl groups wherein an aryl portion thereof is unsubstituted or substituted with one to three substituents selected from the group consisting of C1–C6alkyl groups, halo and CF3; and (CH2)nOR′ wherein n is an integer from 1 to 3 and R′ represents a C6–C10aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1–C6alkyl groups, halo and CF3; B is selected from OR″ and NHR″ wherein R″ is C1–C6alkyl groups; andrepresents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

REFERENCES:
patent: 3920723 (1975-11-01), Nelson
patent: 3931279 (1976-01-01), Nelson
patent: 4504417 (1985-03-01), Floyd, Jr. et al.
patent: 5223537 (1993-06-01), Stjernschantz et al.
patent: 5359095 (1994-10-01), Resul
patent: 5688819 (1997-11-01), Woodward et al.
patent: 5698733 (1997-12-01), Hellberg et al.
patent: 6689901 (2004-02-01), Henegar
patent: 2003/0187071 (2003-10-01), Henegar
patent: 0 178 139 (1986-04-01), None
patent: 1 501 864 (1978-02-01), None
patent: 1 582 853 (1981-01-01), None
patent: 57-171965 (1982-10-01), None
patent: 59-44336 (1984-03-01), None
patent: 60-166639 (1985-08-01), None
patent: 1-228933 (1989-09-01), None
patent: WO-02/090324 (2002-11-01), None
patent: WO-02/096868 (2002-12-01), None
Hazato et al., “Synthesis of Thiaprostaglandin E1Derivatives,”Chem. Pharm. Bull., vol. 33, No. 5, 1985, pp. 1815-1825.
Fox et al., “An Enantioconvergent Synthesis of (R)-4-Aryloxy-1-butyne-3-ols for Prostanoid Side Chains,”Adv. Synth. Catal., vol. 344, No. 1, 2002, pp. 50-56.
Maruyama et al., “Design and Synthesis of a Selective EP4-Receptor Agonist. Part 1: Discovery of 3,7-DithiaPGE1Derivatives and Identification of Their(ω)Chains,”Bioorganic&Medicinal Chemistry, vol. 10, 2002, pp. 975-988.
Robert Selliah et al., “Synthesis of [Phenyl-2-3H]-travoprost: Isopropyl Ester Prodrug of a Selective Prostaglandin FP Receptor Agonist,”Journal of Labelled Compounds and Radiopharmaceuticals, 2001, vol. 44, pp. 173-183.
Hisao Nakai et al., “Synthesis of 5-Fluoro-Prostaglandins,”Chemistry Letters, 1979, pp. 1499-1502.
John C. Sih et al., “Synthesis of the Four Isomers of 5-Hydroxy-PGI1,”Prostaglandins, 1978, vol. 15, No. 3, pp. 409-421.
Zuyun Cai et al., “Synthesis of Aromatic Modified Prostaglandins from PGA2,”J. Chem. Soc. Perkin Trans. I, 1983, vol. 7, pp. 1573-1578.
Paul W. Collins and Stevan W. Djuric, “Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs,”Chem. Rev., 1993, vol. 4, pp. 1533-1564.
Chen Jianxing, Chen Hailin, and Chen Liangkang, “Synthesis of the Antiglaucoma Drug Latanoprost and its Effect on Reduction of Intraocular Pressure (IOP),”Chinese Journal of Medicinal Chemistry, Sep. 1988, vol. 8, No. 3, pp. 213-217.

Affiliated with

Also associated with

Rating

Protected and unprotected triols for prostaglandin synthesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protected and unprotected triols for prostaglandin synthesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protected and unprotected triols for prostaglandin synthesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3669357